Highlights and Quick Summary
- Research and Development Expense of Revenue for the quarter ending May 31, 2022 was 3.6% (a -3.23% decrease compared to previous quarter)
- Year-over-year quarterly Research and Development Expense of Revenue decreased by -21.91%
- Annual Research and Development Expense of Revenue for 2021 was 4.36% (a 198.63% increase from previous year)
- Annual Research and Development Expense of Revenue for 2020 was 1.46% (a 186.27% increase from previous year)
- Annual Research and Development Expense of Revenue for 2019 was 0.51% (a Infinity% increase from previous year)
- Twelve month Research and Development Expense of Revenue ending May 31, 2022 was 3.77% (a -4.56% decrease compared to previous quarter)
- Twelve month trailing Research and Development Expense of Revenue decreased by -14.12% year-over-year
Trailing Research and Development Expense of Revenue for the last four month:
| 31 May '22 | 28 Feb '22 | 30 Nov '21 | 31 Aug '21 |
|---|---|---|---|
| 3.77% | 3.95% | 4.27% | 4.39% |
Visit stockrow.com/OGI
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Research and Development Expense of Revenue of Organigram Holdings Inc.
Most recent Research and Development Expense of Revenueof OGI including historical data for past 10 years.Interactive Chart of Research and Development Expense of Revenue of Organigram Holdings Inc.
Organigram Holdings Inc. Research and Development Expense of Revenue for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | 3.6% | 3.72% | – | – | – |
| 2021 | 3.34% | 4.61% | 4.38% | 5.43% | 4.36% |
| 2020 | 3.29% | 1.89% | 0.98% | 2.02% | 1.46% |
| 2019 | 0.0% | 0.0% | 0.0% | 0.0% | 0.51% |
| 2018 | – | – | 0.0% | 0.0% | 0.0% |
| 2017 | – | – | – | – | 0.0% |
| 2016 | – | – | – | – | 0.0% |
Business Profile of Organigram Holdings Inc.
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic